M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
about
Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disordersChemical lead optimization of a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM) lead. Part II: development of a potent and highly selective M1 PAMM1 receptors mediate cholinergic modulation of excitability in neocortical pyramidal neurons.Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity.Alzheimer's disease: Targeting the Cholinergic SystemThe antipsychotic potential of muscarinic allosteric modulationAllosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.Expanding the multipotent profile of huprine-tacrine heterodimers as disease-modifying anti-Alzheimer agents.Development of allosteric modulators of GPCRs for treatment of CNS disordersGRK5 deficiency accelerates {beta}-amyloid accumulation in Tg2576 mice via impaired cholinergic activity.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Advances in recent patent and clinical trial drug development for Alzheimer's disease.Malignant synaptic growth and Alzheimer's disease.Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficitsCholinergic system during the progression of Alzheimer's disease: therapeutic implications.Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.Intact attentional processing but abnormal responding in M1 muscarinic receptor-deficient mice using an automated touchscreen method.Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: a review.Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems.Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.M1 muscarinic acetylcholine receptor in Alzheimer's diseaseInsights into the structural biology of G-protein coupled receptors impacts drug design for central nervous system neurodegenerative processes.The Distinct Role of ADAM17 in APP Proteolysis and Microglial Activation Related to Alzheimer's Disease.Hybrids: a new paradigm to treat Alzheimer's disease.Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.Molecular Pathogenesis of Alzheimer's Disease: An Update.Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.Loss of muscarinic M1 receptor exacerbates Alzheimer's disease-like pathology and cognitive decline.Activation of M2 muscarinic receptors leads to sustained suppression of hippocampal transmission in the medial prefrontal cortex.Synthesis of novel and functionally selective non-competitive muscarinic antagonists as chemical probes.Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors.
P2860
Q24605472-5684F12A-3A6B-47D1-9A38-CC8F9A9B138EQ24631627-65431902-DEDB-4FE6-AD74-C23C5F2530B6Q24653082-CDE0A682-8945-446E-A192-B6D3C06E7B91Q24657902-69657CD6-BEAB-4E9A-983F-B55C53651422Q28070135-FC476D5F-DAA9-411A-8159-C08026CFAEE2Q28603221-C350D8B7-42FF-4F16-AF63-D090399D0260Q30388923-3F13019C-E06E-4507-A8B6-DFA5A28B43E1Q30474039-A494F968-B75B-4073-AD3C-5E7A8CE28434Q34124395-3648478D-A7D1-40F9-92A1-99F7B92921ECQ34373958-B2DEE924-22DB-4D2B-9C2B-22018CD17CCCQ34438832-81A909DB-187E-4CF4-8F4F-D4B455C1B4EDQ35614156-D09947ED-7850-47DA-AD81-D29BE64B5CFDQ35738142-DA8A9A8D-85C4-4BEB-B4CB-F94D2EA2FF27Q36607929-C209259D-B178-4F09-BA4B-BEF14519DDFDQ37025888-211826C0-613D-4F5A-818A-D13F9CFD311AQ37318152-FB5FED0A-6A69-4EBA-8170-84946BA60A07Q37416470-E07A295F-B868-4E09-AF7F-A5CF157F72F7Q37506679-70DC579A-518E-4EE7-87E5-4E36A3C14011Q37920918-73696683-0ABD-43BA-AA18-9F075B88229FQ38002193-C04E973D-B979-49A7-AB61-954FF6CC2F8DQ38127470-4F7EE89C-ABDA-4051-BC59-B1AC9A530006Q38192962-E69C3436-21E6-4E4F-A7AF-F28A03BC8AD7Q38247995-DBB8DF8F-52CF-4C62-9EBA-8F478C8AD4BEQ38539526-E0E1162D-D1AE-406D-BBC7-D7B70A373676Q38578336-C43E0F1A-AE9C-4A07-A8E0-BB48A27DB930Q38665289-7E2B08B2-C4A1-456E-AD4F-2278FB4727DEQ39355183-C7A46228-194C-4D8F-8D65-B379D61E72CDQ42093765-D5C6B489-4C04-4843-A695-00D0E6A8D000Q42131298-89E0EBEC-BD45-4AFC-A006-9974C9A529ECQ43276901-87B06229-E508-4ED7-B2CC-8F26088B3BA6Q48226745-00F3B0E6-B1E1-4365-B8D4-DD03431ED011Q50694188-082667D4-9CBC-4982-A735-A14EE878DCFB
P2860
M1 muscarinic agonists target major hallmarks of Alzheimer's disease--the pivotal role of brain M1 receptors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@en
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@nl
type
label
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@en
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@nl
prefLabel
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@en
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@nl
P2860
P356
P1476
M1 muscarinic agonists target ...... al role of brain M1 receptors.
@en
P2093
Abraham Fisher
P2860
P304
P356
10.1159/000113712
P577
2008-03-06T00:00:00Z